MTHFD1 deficiency is a rare genetic disease that damages immunity and causes severe anemia, but folic acid therapy can dramatically improve outcomes if started early. Research shows one child with this condition recovered significantly after folic acid supplementation, while another child’s illness progressed too rapidly despite intensive treatment, highlighting that prompt genetic diagnosis and immediate folate therapy are critical for survival.
Researchers in Kuwait discovered two children with a rare genetic condition called MTHFD1 deficiency that damages the immune system and causes severe anemia. This condition makes it hard for the body to use folate (a B vitamin), leading to repeated infections and blood problems. One child improved dramatically after receiving folic acid supplements, while the other sadly did not survive despite intensive treatment. According to Gram Research analysis, this case study highlights how quickly genetic testing and early folic acid therapy can save lives in children with mysterious immune and blood disorders.
Key Statistics
A 2026 case report of two Kuwaiti children with MTHFD1 deficiency found that one 10-year-old girl showed significant clinical improvement with folic acid supplementation, while a 3-year-old girl developed fatal complications despite aggressive treatment including antibiotics, antifungals, and immunoglobulin therapy.
Both children in the 2026 case study carried the identical homozygous genetic mutation (c.517C>T) in the MTHFD1 gene, yet had dramatically different outcomes, suggesting that early diagnosis and prompt folic acid therapy are critical factors determining survival in this rare immune disorder.
The 2026 case report emphasizes that genetic testing should be performed urgently in children presenting with unexplained megaloblastic anemia, recurrent sinopulmonary infections, failure to thrive, and developmental delay, as precision therapy with folate supplementation can significantly improve outcomes.
The Quick Take
- What they studied: How a rare genetic disease affecting folate metabolism presents in children and whether folic acid treatment helps
- Who participated: Two unrelated Kuwaiti girls (ages 3 and 10) with the same genetic mutation causing MTHFD1 deficiency
- Key finding: One child recovered significantly with folic acid therapy, while the other developed severe complications despite aggressive treatment, showing that early diagnosis and prompt supplementation are critical
- What it means for you: If your child has unexplained anemia, repeated infections, and slow growth, genetic testing for MTHFD1 deficiency could identify a treatable condition. Early folic acid supplementation may prevent serious complications, though outcomes depend on how quickly the diagnosis is made
The Research Details
This research describes two real-world cases of children with the same rare genetic disease. The researchers documented what symptoms each child experienced, what tests showed, and how they responded to treatment. This type of study, called a case report, is valuable for rare diseases because it’s difficult to find many patients with the same condition. The doctors carefully tracked each child’s medical history, blood tests, immune function, and response to folic acid supplementation over time.
Both children had the identical genetic mutation (c.517C>T) in the MTHFD1 gene, which controls how the body processes folate—a crucial B vitamin needed for making new blood cells and supporting the immune system. By comparing these two cases, researchers could see how the same genetic defect can cause different outcomes depending on when treatment starts and how severe the initial illness becomes.
Case reports like this are especially important for rare genetic diseases because they help doctors recognize patterns they might otherwise miss. When a child has mysterious symptoms that don’t fit typical diagnoses, knowing about MTHFD1 deficiency could prompt genetic testing that leads to life-saving treatment. This study emphasizes that genetic testing should happen quickly when children have combined immune problems and blood disorders, rather than waiting months for answers.
This is a detailed clinical case report from a respected pediatric medical journal. The strength of this study is its thorough documentation of two patients with confirmed genetic testing. The limitation is that it only describes two children, so we cannot draw broad conclusions about how common this disease is or how many patients would respond to folic acid like the first child did. The contrasting outcomes (one survivor, one fatality) show that timing and disease severity matter significantly.
What the Results Show
The first patient, a 10-year-old girl, presented with unexplained anemia (low red blood cells), repeated lung and sinus infections, failure to gain weight normally, and delayed development. She also developed an autoimmune thyroid condition. When doctors gave her folic acid supplements, her condition improved significantly—her blood counts improved, infections decreased, and she began developing normally.
The second patient, a 3-year-old girl, became critically ill with severe pneumonia and sepsis (blood infection). Despite receiving antibiotics, antifungal medications, immunoglobulin infusions, and steroids, her condition worsened. She developed bone marrow failure (the body stopped making blood cells) and signs of hemophagocytic lymphohistiocytosis (a dangerous immune overreaction). She passed away 18 days after admission to intensive care.
Both children had the same genetic mutation, but their outcomes differed dramatically. The key difference appears to be that the first child’s condition was recognized and treated earlier with folic acid, while the second child’s illness progressed too far before the genetic diagnosis was confirmed.
Both children showed megaloblastic anemia, a specific type of anemia where red blood cells are abnormally large. Both had recurrent infections affecting the lungs and sinuses. Both showed failure to thrive (not growing and developing normally). The first child also had autoimmune thyroiditis (her immune system attacked her thyroid). The second child developed bone marrow failure, where the bone marrow stopped producing blood cells. These findings suggest MTHFD1 deficiency affects multiple body systems—the blood, immune system, and growth.
MTHFD1 deficiency is extremely rare, with only a handful of cases reported worldwide. This case report adds to the limited medical literature on this condition and confirms that folic acid supplementation can be effective. Previous reports have suggested that early diagnosis and prompt folate or folinic acid therapy improve outcomes, and this case study supports that finding. However, it also shows that if the disease progresses to severe complications like sepsis and bone marrow failure, even intensive treatment may not be successful.
This study describes only two children, so we cannot determine how common this disease is or predict how many patients would respond to folic acid therapy. We don’t know the long-term outcomes for the first child beyond the initial improvement. The study doesn’t include detailed information about the exact dose of folic acid used or the timeline of improvement. Because this is a case report rather than a controlled study, we cannot compare outcomes to other treatments or determine which factors most strongly predict survival. The genetic mutation found in these two Kuwaiti children may be more common in certain populations, so results may not apply equally to all ethnic groups.
The Bottom Line
If your child has unexplained anemia, repeated infections, poor growth, and developmental delay, ask your pediatrician about genetic testing for MTHFD1 deficiency (confidence: moderate, based on case evidence). If MTHFD1 deficiency is diagnosed, folic acid or folinic acid supplementation should begin immediately (confidence: high, based on one successful case). Early diagnosis and treatment appear critical for preventing severe complications (confidence: moderate, based on contrasting outcomes in two cases).
Parents of children with unexplained anemia and recurrent infections should know about this condition. Pediatricians and immunologists should consider MTHFD1 deficiency in children with combined immune deficiency and blood disorders. Genetic counselors should be aware of this condition when counseling families with consanguinity (related parents), as this increases the risk of rare genetic diseases. Children with confirmed MTHFD1 deficiency and their families should receive genetic counseling.
The first child showed significant improvement within weeks to months of starting folic acid therapy. However, the second child’s illness progressed rapidly over 18 days despite intensive treatment. The timeline for improvement depends on how advanced the disease is at diagnosis. Early diagnosis and treatment may prevent progression to severe complications.
Frequently Asked Questions
What is MTHFD1 deficiency and how does it affect children?
MTHFD1 deficiency is a rare genetic disease where the body cannot properly use folate (a B vitamin), leading to weak immunity, severe anemia, repeated infections, poor growth, and developmental delays. Early folic acid treatment can prevent serious complications.
Can folic acid supplements treat MTHFD1 deficiency?
Yes, according to a 2026 case report, folic acid supplementation led to significant improvement in one child with MTHFD1 deficiency, including better blood counts and fewer infections. Early diagnosis and prompt treatment appear essential for success.
What symptoms should make me suspect my child has MTHFD1 deficiency?
Seek genetic testing if your child has unexplained anemia, repeated ear/sinus/lung infections, failure to gain weight normally, developmental delays, or autoimmune conditions. A 2026 case study found these symptoms in children with MTHFD1 deficiency.
How quickly does folic acid therapy work for MTHFD1 deficiency?
One child in a 2026 case report showed significant improvement within weeks to months of starting folic acid therapy. However, outcomes depend on disease severity at diagnosis—advanced cases may not respond despite intensive treatment.
Is MTHFD1 deficiency hereditary and can it be prevented?
Yes, MTHFD1 deficiency is inherited when both parents carry the same genetic mutation. It cannot be prevented, but early genetic diagnosis and folic acid therapy can prevent severe complications and improve survival outcomes.
Want to Apply This Research?
- Track your child’s infection frequency (number of ear, sinus, or lung infections per month), energy levels (1-10 scale), and growth metrics (height and weight percentiles) monthly to monitor response to folic acid supplementation
- Set daily reminders to give folic acid supplements at the same time each day, and maintain a symptom diary noting infections, energy, appetite, and developmental milestones to share with your pediatrician
- Schedule quarterly check-ins with your pediatrician to review blood work (CBC, folate levels), infection rates, and growth progress. Use the app to track trends over 3-6 months to assess whether folic acid therapy is working effectively
This article describes a rare genetic case and is for educational purposes only. MTHFD1 deficiency is extremely rare and requires specialized medical diagnosis and treatment. If your child has unexplained anemia, recurrent infections, or developmental delays, consult your pediatrician or a pediatric immunologist for proper evaluation. Do not start folic acid supplementation without medical supervision, as dosing must be individualized. Genetic testing should only be ordered and interpreted by qualified healthcare providers. This case report describes two individual patients and cannot be generalized to predict outcomes for all children with this condition.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.